F-598 is under clinical development by Alopexx and currently in Phase II for Hospital-Acquired Infections. According to GlobalData, Phase II drugs for Hospital-Acquired Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the F-598 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

F-598 overview

F598 (SAR-279356) is under development for the treatment of poly-N-acetylglucosamine (PNAG) infections, S. pneumoniae-induced Pneumonia, gram-negative bacterial infections, hospital-acquired infections, gram-positive bacterial infections, fungal infections, pulmonary tuberculosis and for the prevention of infection after emergency abdominal surgery or abdominal trauma. The therapeutic candidate binds to a conserved surface polysaccharide known as poly-N-acetyl glucosamine (PNAG). F598 is a fully human monoclonal antibody. The drug is administered through intravenous infusion. It was under development for prevention and treatment of serious bacterial infections like gonorrhea in intensive care unit (ICU) patients on mechanical ventilation.

Alopexx overview

Alopexx is a clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics. Alopexx is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of F-598’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.